The cannabidiol market is estimated to be valued at USD 9.46 Bn in 2025 and is expected to reach USD 27.57 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.5% from 2025 to 2032.
To learn more about this report, Download Free Sample
The cannabidiol market is expected to witness stable growth over the forecast period, owing to increased investments in research & development and legalization of medical cannabis across various countries. With growing health awareness and acceptance of medical benefits of cannabidiol in various health conditions, the market is expected to attract higher investments globally. Furthermore, adoption of cannabidiol as a potential alternative to opioid drugs can offer new growth avenues for market players in the near future.
However, variable legislation around use of cannabidiol products and lack of clinical evidence can hamper the market growth. Focus on development of innovative delivery formats and establishing standards through clinical research can provide new growth opportunities in the near future.
To learn more about this report, Download Free Sample
|
Current Events |
Description and its impact |
|
Regulatory and Legal Developments |
|
|
Economic Trends and Investment Flows |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The global CBD market is expanding rapidly, driven by consumer demand for natural health, wellness, and beauty solutions. As regulations evolve across North America, Europe, Asia Pacific, and Latin America, international trade in CBD products is opening new frontiers.
The cannabidiol market is experiencing significant expansion largely due to the growing acceptance and legalization of cannabis-derived products worldwide. This shifting regulatory landscape has played a crucial role in destigmatizing cannabis and its derivatives, paving the way for increased consumer interest and broader product innovation. Consumers are increasingly using CBD for a variety of health purposes such as stress relief, pain management, and sleep aid.
For instance, the 2022 National Survey on Drug Use and Health (NSDUH) by the Substance Abuse and Mental Health Services Administration (SAMHSA) reported a notable increase in the use of cannabis products, indicative of broader normalization.
In terms of source type, the hemp segment is estimated to contribute the highest market share of 58.6% in 2025, owing to its versatile applications across industries.
Hemp contains only trace amounts of THC but is highly rich in cannabidiol, making it legal for use in food & beverages, cosmetics, pharmaceuticals and other consumer products. This wide scope of legal use provides hemp a significant advantage over marijuana-derived cannabidiol. Hemp farmers can use established agricultural practices to grow the crop on a large commercial scale due to its low maintenance requirements.
In terms of product, oil segment is estimated to contribute the highest market share owing to its easy administration and high bioavailability. Cannabidiol oil extract is valued for its therapeutic benefits in treating a variety of medical conditions like pain, anxiety, epilepsy and even cancer.
The oil concentrate derived from hemp or marijuana plants has high cannabidiol contents ranging between 2 and 30.5% that can treat symptoms effectively. Its application as an oral tincture makes cannabidiol oil highly convenient to use. Users administer drops of the oil under their tongue to gain almost immediate relief from symptoms. Moreover, its absorption through the oral mucous membrane and direct entry into blood circulation provides optimal bioavailability compared to other products.
In terms of application, the medical segment is estimated to contribute the highest market share owing to the growing acceptance of cannabidiol-based therapies. While consumer use of cannabidiol for relaxation and wellness has increased significantly, its role in improving medical outcomes through clinical research validates therapeutic applications.
An increasing number of patients are turning to Cannabidiol to manage chronic conditions instead of synthetic pharmaceuticals due to cannabidiol's natural profile and lack of psychoactive effects. Research studies have demonstrated cannabidiol's potential against neurological disorders, reducing epileptic seizures and easing psychotic episodes in schizophrenics. It shows promise for relieving cancer treatment side effects and may work synergistically with conventional therapies.
|
Price-Per-mg Benchmarking (Quick Reference) |
Price Range (USD) |
|
Entry-level tincture/capsule |
0.02–0.05/mg |
|
Mainstream reputable brands |
0.03–0.10/mg |
|
Gummies/topicals |
0.06–0.25/mg (higher variability) |
|
Beverages/patches/specialty |
0.10–1.00+/mg |
|
Wholesale isolate |
0.0015–0.006/mg (per kg pricing) |
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Download Free Sample
North America is estimated to hold a dominant position in the global cannabidiol market over the forecast period. North America is estimated to hold 40.7% of the market share in 2025. One of the leading subsegments in North America is the cannabidiol-based therapeutic products segment. This segment dominates due to the rapid adoption of CBD in the pharmaceutical and healthcare sectors, driven largely by increasing research validating the medicinal benefits of cannabidiol for conditions like epilepsy, chronic pain, anxiety, and inflammation.
For instance, according to the National Organization for the Reform of Marijuana Laws (NORML), an analysis published in February 2025 of data from Preventive Medicine Reports found that approximately 10.5 percent of Americans reported using CBD products in the past 30 days.
Asia Pacific has emerged as the fastest growing regional market for cannabidiol. Governments and healthcare organizations across the region have increasingly recognized the therapeutic potential of cannabidiol, positioning it as a critical player in managing chronic pain, epilepsy, anxiety, and other neurological disorders. In addition to legislative support, countries like Japan and South Korea have seen a surge in clinical research collaborations between biotech firms and universities focusing on CBD’s neuroprotective and anti-inflammatory properties, which further legitimizes and drives demand within pharmaceutical channels.
For instance, Australia has taken pioneering steps in integrating CBD-based drugs into its pharmaceutical landscape, evidenced by the country’s regulatory approval of pharmaceutical-grade CBD products like Epidyolex for epilepsy treatment, which has catalyzed demand in its domestic market.
Latin America is fast emerging as one of the most dynamic regions for cannabidiol (CBD). With progressive regulation in countries like Brazil, Mexico, Colombia, Uruguay, and Argentina, CBD is moving from niche medical use into mainstream wellness. Consumers are increasingly embracing CBD as a natural alternative for managing pain, anxiety, sleep, and overall well-being.
Favorable climates and low cultivation costs make the region a strategic hub for CBD production, with countries such as Colombia and Uruguay positioned as future exporters to global markets. Growing consumer awareness and expanding retail channels, including pharmacies and e-commerce platforms, are accelerating adoption.
The U.S. is the largest cannabidiol market globally, owing to federal reforms like the Agricultural Improvement Act of 2018 that legalized hemp cultivation. This legislation enabled commercial production and interstate transport of hemp-derived products. State-level legalization and consumer demand for wellness solutions further boost the CBD ecosystem. The U.S. leads in product development, retail distribution, and industry innovation across the CBD space.
Canada was among the first nations to legalize both medical and recreational cannabis under the Cannabis Act in 2018. This regulatory clarity created a structured, high-compliance market for CBD and cannabis derivatives. A robust licensing system enabled safe, traceable production and distribution of CBD products. Canada’s mature legal framework supports ongoing innovation and consumer protection in the industry.
China dominates global hemp output, accounting for more than 70% of world production. This massive supply capacity positions China as a key global source of raw materials for CBD manufacturing. Low-cost production and established agricultural infrastructure make Chinese-sourced hemp highly competitive internationally. Countries across Europe and North America often rely on Chinese hemp inputs for their CBD supply chains.
Germany has emerged as Europe’s most dynamic CBD and medicinal cannabis market. Extensive reforms—including liberalized prescription policies—have made medical cannabis widely accessible. Recent legislative changes have eliminated cannabis from narcotics controls, expanding patient access and import volumes. As a result, Germany plays a central role in driving European CBD adoption and regulatory evolution.
|
Drug Category |
Price Range per Treatment Cycle/Month (USD) |
|
Chemotherapy |
USD 300 – USD 1,800 |
|
Targeted Therapies |
USD 3,500 – USD 13,000 |
|
Immunotherapy |
USD 10,000 – USD 15,000 per dose |
|
Bone-Modifying Agents |
USD 500 – USD 4,200 per dose |
|
Supportive Care |
USD 20 – USD 3,000 |
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 9.46 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 16.5% | 2032 Value Projection: | USD 27.57 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
ENDOCA, Cannoid LLC, Medical Marijuana Inc., Folium Biosciences, Elixinol, NuLeaf Naturals LLC, Isodiol International Inc., Pharmahemp d.o.o., Aurora Cannabis Inc., CV Sciences, Medterra CBD, Canopy Growth Corporation, Aphria, Inc., GW Pharmaceuticals Plc, and Organigram Holding Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
|
Country/Region |
Market posture |
Food/Supplements |
Cosmetics/Topicals |
Medical Use |
|
U.S. |
Fragmented – federal vs. state patchwork; hemp CBD widely sold but FDA has no supplement pathway |
Not permitted federally (FDA bars CBD in foods/dietary supplements); many states allow retail anyway |
Permitted if <0.3% THC and no drug claims; rules vary by state |
Yes, but only FDA-approved Epidiolex; other CBD not recognized as medicine |
|
European Union |
Structured but restrictive – harmonized rules, Member State variations |
Requires EU Novel Food authorization; pending applications create bottleneck |
Permitted for certain ingredients under CosIng (Cosmetics Ingredients Database) if THC-free |
Allowed under Member State medical cannabis frameworks; not harmonized EU-wide |
|
Canada |
Strictly regulated – all CBD treated as cannabis |
Only sold via licensed cannabis channel, not as natural health products (NHPs); consultation underway for future OTC path |
Allowed as cannabis topicals via licensed retailers |
Yes, via prescription or recreational channel; regulated under the Cannabis Act |
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
*Definition: The cannabidiol market encompasses the production, distribution, as well as sale of CBD—a non‑psychoactive compound derived primarily from hemp—used across pharmaceutical, wellness, food and beverage, cosmetics, pet care industries, etc. This market is shaped by evolving global regulations, expanding health and therapeutic applications, and rising consumer demand for natural health solutions.
Share
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
